REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2022 >

Decisions 13th September 2022

Decisions 13th September 2022

At the meeting on the 13th September, the following decisions were agreed


New Drug Requests


Perflutren (Luminity) (TLS Red)

  • For ultrasound contrast-enhancing agent for use in adult patients as an alternative to SonoVue

Tretinoin 0.025% / Clindamycin 1% Gel (TLS Green)

  • For acne

  • Tretinoin/Erythromycin removed from the Formulary

 Synalar® (fluocinolone ointment 0.025%) ointment/cream (TLS Blue)

  • For severe inflammatory skin disorders such as eczema and psoriasis

  • Synalar gel (already on formulary) TLS changed from green to blue inline with other formulations of Synalar.


Not Approved

Melatonin (Adults)

  • Off-label use in patients with dementia experiencing circadian sleep disorders, in whom conventional sedation is considered too risky


Decision Pending 

Melatonin (Adults and Paediatrics)

  • Off-label use for sleep disorder in adult and paediatric patients with any of:

    • Attention Deficit Hyperactivity Disorder (ADHD)

    • Autism Spectrum Disorder (ASD)

    • Learning Disabilities (LD)


Other Formulary Decisions

  • Roxadustat for treating symptomatic anaemia in chronic kidney disease as per NICE TA807 added to Formulary as TLS Red in line with updated NICE TA resource impact report.

  • Alprostadil listing updated to include all available brands (Caverject and Viridal Duo) to support with recent supply problems. The lowest acquisition cost should be prescribed and brands should not be changed without appropriate patient counselling.

  • Sip feed chapter review – proposed amendments approved